From selection hits to clinical leads: progress in aptamer discovery.
From selection hits to clinical leads: progress in aptamer discovery.
复制标题
DOI：
10.1038/mtm.2016.14
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Levy M
中科院分区：
文献类型：
--
作者：
Maier KE;Levy M
适配体是在25年前发现的，但迄今为止只有一种被美国食品和药物管理局批准。随着它们的化学设计和我们用来制造它们的酶的一些值得注意的进展，适体和基于适体的治疗剂已经看到了兴趣的复苏。新的适体药物正在被批准用于临床评估，可以肯定的是，我们将在未来看到越来越多的适体和适体样药物。在这篇综述中，我们将讨论适体的生产，重点是使早期适体在临床试验中取得成功的进展和修饰，以及那些可能对这些药物的后代很重要的进展和修饰。
Aptamers were discovered more than 25 years ago, yet only one has been approved by the US Food and Drug Administration to date. With some noteworthy advances in their chemical design and the enzymes we use to make them, aptamers and aptamer-based therapeutics have seen a resurgence in interest. New aptamer drugs are being approved for clinical evaluation, and it is certain that we will see increasingly more aptamers and aptamer-like drugs in the future. In this review, we will discuss the production of aptamers with an emphasis on the advances and modifications that enabled early aptamers to succeed in clinical trials as well as those that are likely to be important for future generations of these drugs.